Rituximab

The importance of assessing autoreactive T-cell responses in MS 2:25
The importance of assessing autoreactive T-cell responses in MS
Olivia Thomas • 21 Oct 2021
Comparing exit strategies in natalizumab-responders at high risk for PML 7:33
Comparing exit strategies in natalizumab-responders at high risk for PML
Emanuele D'Amico • 30 Sep 2021
COVID-19 vaccination in patients with MS 7:22
COVID-19 vaccination in patients with MS
Maria Pia Sormani • 13 Oct 2021
COVID-19 cases in MS patients receiving IV therapy 1:49
COVID-19 cases in MS patients receiving IV therapy
Celia Oreja-Guevara • 14 Oct 2021
How does ublituximab compare to other anti-CD20 mAbs? 1:14
How does ublituximab compare to other anti-CD20 mAbs?
Lawrence Steinman • 15 Oct 2021
Humoral response to COVID-19 vaccination in patients with MS 6:28
Humoral response to COVID-19 vaccination in patients with MS
Celia Oreja-Guevara • 14 Oct 2021
Real-world comparison of natalizumab exit strategies in patients with RRMS 9:25
Real-world comparison of natalizumab exit strategies in patients with RRMS
Aurora Zanghì • 22 Jun 2021
Update on pediatric NMOSD and MOGAD 3:47
Update on pediatric NMOSD and MOGAD
Brenda Banwell • 26 Apr 2021
Determining the optimal treatment strategy in MS 4:18
Determining the optimal treatment strategy in MS
Tanuja Chitnis • 23 Feb 2021
The content of VJNeurology is intended for healthcare professionals